Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer.
Proteomics is a powerful technique for investigating protein expression profiles in biological systems and their modifications in response to stimuli or to particular physiological or pathophysiological conditions. It is therefore a technique of choice for the study of drug mode of action, side-effects, toxicity and resistance. It is also a valuable approach for the discovery of new drug targets. All these proteomic applications to pharmacological issues may be called pharmacoproteomics. The pharmacoproteomic approach could be particularly useful for the identification of molecular alterations implicated in type 2 diabetes and for further characterization of existing or new drugs. In oncology, proteomics is widely used for the identification of tumour-specific protein markers, and pharmacoproteomics is used for the evaluation of chemotherapy, particularly for the characterization of drug-resistance mechanisms. The large amount of data generated by pharmacoproteomic screening requires the use of bioinformatic tools to insure a pertinent interpretation. Herein, we review the applications of pharmacoproteomics to the study of type 2 diabetes and to chemoresistance in different types of cancer and the current state of this technology in these pathologies. We also suggest a number of bioinformatic solutions for proteomic data management.
INNODIA S.A.S., 8 rue de l'Ecole Normale, 34296 Montpellier Cedex 5, France. Laurence.molina@ibph.pharma.univ-montp1.fr
Nicolas
N
Chapal
Laurence
L
Molina
Franck
F
Molina
Marion
M
Laplanche
Bernard
B
Pau
Pierre
P
Petit
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019295:Computational Biology / Q000458:organization & administration*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004351:Drug Resistance; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D040901:Proteomics / Q000379:methods*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents